biotech / news / / Devdiscourse
Pfizer, AstraZeneca, Merck, and others are capitalizing on exemptions and direct consumer strategies to mitigate tariff impacts.
Pfizer secured a tariff exemption grace period after committing $70 billion to U.S. operations.
KEY POINTS
- AstraZeneca and Roche are undertaking multi-billion dollar U.S. expansions to retain market share.
- Eli Lilly and Johnson & Johnson are building new U.S. facilities and bolstering local production.
- Pharma companies are adopting direct-to-consumer strategies to minimize the impact of 100% drug tariffs.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →